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Bipolar disorders (BDs) and addictions constitute reciprocal risk factors and are best con-
sidered under a unitary perspective.The concepts of allostasis and allostatic load (AL) may
contribute to the understanding of the complex relationships between BD and addictive
behaviors. Allostasis entails the safeguarding of reward function stability by recruitment of
changes in the reward and stress system neurocircuitry and it may help to elucidate neuro-
biological underpinnings of vulnerability to addiction in BD patients. Conceptualizing BD as
an illness involving the cumulative build-up of allostatic states, we hypothesize a progres-
sive dysregulation of reward circuits clinically expressed as negative affective states (i.e.,
anhedonia). Such negative affective states may render BD patients more vulnerable to drug
addiction, fostering a very rapid transition from occasional drug use to addiction, through
mechanisms of negative reinforcement. The resulting addictive behavior-related ALs, in
turn, may contribute to illness progression. This framework could have a heuristic value to
enhance research on pathophysiology and treatment of BD and addiction comorbidity.
Keywords: bipolar disorders, addiction vulnerability, allostasis and allostatic load, comorbidity, hedonic tone and
anhedonia, dopaminergic system, reward system, CRF/HPA axis and stress system
INTRODUCTION
Bipolar disorder (BD) is a severe, often chronic condition with
lifetime prevalence rates of up to 6.5% for bipolar spectrum
disorders in the general population (1). BD patients frequently
report co-occurring substance-use disorders (SUDs) and behav-
ioral addictions (1–5). The rates of alcohol and other SUDs
are significantly higher in subjects with BD than in the gen-
eral population (1, 6). The co-occurrence of BD and addiction
has important clinical implications (3, 7). Bipolar patients with
comorbid conditions present with a more severe course of ill-
ness (8), characterized by an overall worse clinical picture (9),
poorer treatment outcome (10–12), higher suicidality (13), and
mortality (14).
Several studies have aimed to identify the endophenotypi-
cal features predisposing to the development of addiction in
the general population, as well as in the context of BD. These
studies focused on genetic vulnerability, impulsive traits, and
decision-making impairment (15–19).
The aim of this paper is to present the possible contribution of
the concept of allostasis as a framework linking BD and addiction.
We hypothesize that the concepts of allostasis and allostatic load
(AL) may contribute to the understanding of the complex rela-
tionships between BD and addictive behaviors (20–22). Allostasis
entails the safeguarding of reward function stability by recruit-
ment of changes in the reward and stress system neurocircuitry
Abbreviations: AL, allostatic load; BD, bipolar disorder; CRF, corticotropin-
releasing factor; GD, gambling disorder; HPA, hypothalamic-pituitary-
adrenocortical (axis); SUD, substance-use disorder.
(21) and it may help to elucidate neurobiological underpinnings
of vulnerability to addiction in BD patients.
METHODS
Computerized database, i.e., PubMed, Psycinfo, Cochrane Library
were searched using the following terms: “allostasis,” “AL,”
“reward,” “hedonic tone,” “stress system” cross-referenced with
“BD,” “addiction,” and “SUDs.” The results of this search are pre-
sented in this article,and examined in light of a unifying hypothesis
with a potential heuristic value to inform and provide direction to
future research in this intriguing area.
RELEVANCE OF ALLOSTASIS IN BD AND ADDICTION FIELD
BIPOLAR DISORDERS
Bipolar disorders is a complex and multifactorial disease, with
genetic and environmental factors contributing to its clinical
expression (23). BD can also be conceptualized as an illness involv-
ing the cumulative build-up of allostatic states, whereas AL pro-
gressively increases as stressors and mood episodes occur over time
(24). Indeed, it has been postulated that mood episodes function
as allostatic states, generating a load that is responsible for illness
progression commonly seen in BD (25, 26). AL may contribute
to a better understanding of BD, particularly of inter-episodic
phenomena such as vulnerability to stress, cognitive symptoms
(26), and higher physical comorbidity rates (24). BD patients
present with alterations in major mediators of AL. They exhibit for
instance, persistent dysregulation of the hypothalamic-pituitary-
adrenocortical (HPA) axis, circadian rhythm disturbances, altered
immunity as well as pro-inflammatory and oxidative stress states
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[please refer to the review Kapczinski et al. (24)]. Neurotrophic
factors play an important role in maintaining a physiological brain
function. They have been shown to be modulated by environmen-
tal events in various psychopathological conditions (27), and their
role has been confirmed also in pathophysiology and staging of
BD (28–31).
These alterations are greater during the acute stages of the dis-
ease, but remain sub-threshold even during remission (24). When
mediators of allostasis – essential for brain functioning and pro-
tection – are driven by mechanisms of homeostatic dysregulation,
they act in excess and damage brain tissue (32, 33), which is par-
ticularly vulnerable to the harmful effects of the AL [i.e., oxidative
stress (34)]. Impairment in the stress response has been acknowl-
edged as a core feature of BD clinical expression, as well as having
a central role in the concept of AL (23). Although the exact mecha-
nisms, by which stress exerts its effect on the brain, remain largely
unknown, the HPA axis is one of the main stress response sys-
tems activated with the objective to maintain stress adaptation for
as long as it is necessary (23). The HPA axis is clearly altered in
mood disorders, as well as in BD (35–38). Glucocorticoids play an
important role in the process whereby the mediators of allostasis
interact with neurotransmitter systems and brain peptides result-
ing in neuroplastic alterations in the hippocampus, amygdala, and
prefrontal cortex (39, 40). The role of stress in triggering mood
episodes is well established, particularly in the early stages of ill-
ness (41, 42). It has been hypothesized that early life stress could
affect the endocrine system, producing a stable reprograming of
HPA axis (43), leading to an impairment in brain area involved
in emotional processing (44). Alterations in emotional processing
involving amygdala circuitry and are related to BD symptoms in
several ways. Evidence from amygdala-dependent tasks points to
a dysregulation of amygdala-related neurocircuitry in BD patients
(45). These alterations render BD patients more prone to trigger
AL (23), through a greater stress vulnerability.
ADDICTION
Drug addiction can be conceptualized as a stress-surfeit disorder
(46). It is characterized by the occurrence of an allostatic state
in the brain reward system, reflected in a chronic deviation of
reward thresholds (46–48). An allostatic state reflects a new bal-
ance, a state of chronic deviation of the regulatory system from its
normal (homeostatic) operating level to a pathological (allostatic)
operating level (47). From a drug addiction perspective, repeated
compromised activity in the dopaminergic system and sustained
activation of the corticotropin-releasing factor (CRF) system may
lead to an AL that contributes significantly to the transition from
occasional drug use to drug addiction (49, 50). This model may
be applied to pathological gambling as well (51). The transition
from occasional controlled drug use to loss of control is endorsed
by the emergence of negative affective states, resulting from the
abovementioned allostatic dysregulations (i.e., the AL), with a shift
from impulsivity to compulsivity and from positive reinforcement
to negative reinforcement (49, 52).
Addiction implies dysregulation of the brain reward system
(48, 53). Several studies highlighted that negative affective states
are a result of the alteration of neurobiological elements central to
reward and stress systems (50, 54, 55), in brain areas such as the
ventral striatum and the extended amygdala (56, 57). In addition
to the reduction of dopaminergic and opioidergic functioning,
dysregulation of reward is also mediated by the activation of brain
stress systems (i.e., CRF), in the areas of the extended amygdala
(57). Stress system alterations have been observed in both the
acute and chronic phases of addiction, and seem to play a role
in determining reward dysregulation (48, 54). Acute withdrawal
raises the threshold for reward, leads to an increase in dysphoric
symptoms as well as an increase of CRF levels in the amygdala (49,
58). These changes result from sensitization of the brain stress
system in response to the phenomena of abstinence, and persist
for a long period of time following cessation of drug intake [pro-
tracted withdrawal (59)]. Protracted withdrawal symptoms are
related to the compulsivity characterizing addictive disorders, and
are factors involved in determining relapse. In addition to CRF,
other mediators (norepinephrine, dynorphin, and neuropeptide
Y) have been investigated and found to play a role in the transition
from impulsivity to compulsivity (58, 60). As a whole, these ele-
ments constitute the brain stress system of the extended amygdala,
a counter-adaptive system that interacts with the reward system
and determine its reduced function (48).
NEUROBIOLOGICAL ISSUES OF BD-SUD COMORBIDITY
A complete review of neurobiological features in BD-SUD comor-
bidity is beyond the purpose of this paper. Familial and illness
course characteristics of BD and addictive disorders, as well
as shared underlying mechanisms suggest potentially important
genetic overlap (19, 61, 62). Preliminary findings hint at the exis-
tence of a shared genetic vulnerability for BD and SUDs (15).
Johnson et al. (63) found convergent genome-wide association
results for BD and SUDs. Products of one group of these genes are
likely to play substantial roles in the initial and/or plasticity-related
“wiring” of the brain (63). A second group of genes is the family of
clock genes, implicated in the regulation of behavioral and phys-
iological periodicity (19). Recently, a significant genetic overlap
between candidate genes for both alcoholism and BD was found
(64, 65), by using the d-box binding protein knockout mouse, a
stress-reactive animal model developed consistently with allostasis
and stress-surfeit theory of addiction (46).
To date, no studies have specifically investigated neuroimaging
correlates in comorbid BD–SUD patients. Several studies describe
putative mechanisms involved in BD vulnerability to addiction.
Structural imaging studies in BD patients found volume reduc-
tions in prefrontal cortex [PFC (66)], which is involved in encoding
incentive information (67). During Iowa gambling task (IGT),
BD patients showed abnormalities in the dorsal and ventral PFC,
while lateral temporal and polar regions displayed increased acti-
vation (68). Jogia et al. (69) confirmed these observations and
also reported a greater activation in the anterior cingulate cor-
tex of BD patients performing the IGT and in the insula during
the n-back working memory task. Reduced functioning of the
dopamine transporter (DAT) has been linked to BD (70–72). Ani-
mal models may provide insight into the role of the dopaminergic
system in risk-taking behavior. Mice with reduced DAT function-
ing exhibit a behavioral profile consistent with manic patients and
increased risk-taking behavior during a mouse version of the IGT
(70). Evidence from these animal model studies and translational
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human research in BD subjects (73, 74), allows us to hypothesize
that system-related change involving functioning of the dopamine
system play a role in impulsive choice, risk-taking behavior, and
reward, thus help guiding future studies in BD–SUD subjects.
ALLOSTATIC DYSREGULATION OF REWARD MIGHT
UNDERPIN BIPOLAR VULNERABILITY TO ADDICTION
Dopaminergic mechanisms are likely to play a key role in the
understanding of the pathophysiology of BD and the clinical
phenomena of mania and depression have previously been con-
ceptualized in terms of an increase or a decrease in dopaminergic
function, respectively (75, 76). Also, converging lines of evidence
suggest that dopamine is a key neurotransmitter mediating hedo-
nic allostasis in drug and behavioral addictions (49, 77). From a
neurobiological perspective, a central dopaminergic dysfunction
has been widely proposed as a neurobiological correlate of anhe-
donia (78). Different studies suggest anhedonia as a key symptom
in addictive disorders, both as part of a withdrawal syndrome and
as a relevant factor involved in relapses (51, 59, 79). In addition
to dopamine, other neurotransmitters are believed to encode the
hedonic experience [endogenous opioids, serotonin (80)], while
long-lasting alterations involving cue-induced craving and relapse
are thought to result from neuroplastic changes in glutamatergic
circuitry (81–83).
Several studies provide support for reward dysregulation
accounts in BD (16, 18, 45, 69, 84–95) (Table 1), characteriz-
ing neural dynamics underlying inter-temporal reward processing
(90). Possibly emotional dysregulation present in BD is related
to hypersensitivity to reward-relevant stimuli (93). Impulsive and
unsafe decision-making in BD is linked to decreased sensitivity
to emotional contexts involving rewards or punishments, pos-
sibly reflecting altered appraisal of prospective gains and losses
associated with certain behaviors (89). It has been proposed that
anhedonia could be mediated by a change in reward sensitivity
(78), which has different behavioral consequences involving either
stress-related and dopaminergic processes (96). In BD, sustained
allostatic states and the consequent cumulative brain damage
resulting from increased AL may play a part in the occurrence
of negative affective states (i.e., anhedonia) that persist even dur-
ing periods of remission (84). Counter-adaptive processes, such
as opponent process that are part of the normal homeostatic lim-
itation of reward function (55) fail to return within the normal
homeostatic range and are hypothesized to repeatedly drive the
allostatic state [decreased dopamine and opioid peptide function,
increased CRF activity (49)]. This allostatic state is hypothesized
to be reflected in a chronic deviation of reward set point that is
fueled, not only by dysregulation of reward circuits per se but also
by recruitment of brain and hormonal stress responses.
Altered functioning of the HPA axis may hold clues to the
nature of the motivational changes accompanying addiction and
vulnerability to addiction (97). Pre-existing alterations in frontal–
limbic interactions with the HPA may reflect addiction-proneness,
as shown in studies of offspring of alcohol- and drug-abusing
parents (98). Alterations in the CRF/HPA axis may exert effects
on the corticostriatal-limbic motivational, learning, and adapta-
tion systems that include mesolimbic dopamine, glutamate, and
gamma-amino-butyric acid (GABA) pathways (97), representing
the underlying pathophysiology associated with stress-related risk
of addiction.
The effects of these allostatic changes in the mesocorticolimbic
brain system and in CRF/HPA axis contribute to the underlying
pathophysiology associated with stress-related risk of addiction in
BD (99). In BD patients, we hypothesize that the hedonic response
to an acute drug administration occurs on a pre-existing allostatic
dysregulation of the dopamine and CRF system. BD-related allo-
static alterations in reward and stress systems thereby constitute
vulnerability factors to the development of addiction in subjects
exposed to occasional drug use. The failure to self-regulate these
systems, determined by the collective contribution of endogenous
factors linked to BD and of exogenous substances, results in an AL
leading to a facilitated transition to drug addiction.
Dysphoria triggers drug intake, accompanied by an intense
activity of the dopaminergic system and followed by a compen-
satory decrease in the dopaminergic system and increase in the
CRF system to re-establish the allostatic set point. Such nega-
tive affective states may render BD patients more vulnerable to
drug addiction, favoring a very rapid transition from occasional,
recreational drug use to compulsive, pathological, drug depen-
dence. The resulting addictive behavior-related ALs, in turn, may
contribute to illness progression (Figure 1).
CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES
Converging data from addiction and BD studies suggest that
these disorders involve similar allostatic processes, and allostasis
can contribute to unify these disorders under a unitary perspec-
tive. In this context, the concepts of allostasis and AL provide
both a pathophysiological model for the understanding of BD-
addiction comorbidity and a new perspective for the development
of novel therapeutic strategies for the treatment of comorbid
patients (100, 101).
Allostatic alterations in brain reward system could render BD
patients more vulnerable to drug addiction, favoring a very rapid
transition from occasional, recreational drug use to compulsive,
pathological, and drug dependence. This framework allows us to
explain the high comorbidity rate between these disorders (2), as
well as its relevance in early-onset patients (8, 102). Furthermore,
it enables us to identify the factors of vulnerability to addiction
in inter-episode periods as well (i.e., sub-threshold reward-system
dysfunctions) (84). A more accurate monitoring of comorbidity-
risk (103), coupled with the inclusion of specific tools for the
assessment of hedonic tone, may contribute to early intervention
on addiction-vulnerability factors and to initiate primary pro-
phylaxis for substance misuse in youth suffering from BD with
high-risk for addiction (104–106).
Currently, accruing evidence suggests that mood alteration
episodes increase the risk of substance use (107, 108). Patients with
dual disorders are more likely to use substances to self-regulate
perceived internal factors (109, 110). SUD comorbidity in BD
patients was preceded by greater manic symptoms in the previous
period (104), as well as the persistence of depressive symptoms
was associated with higher craving and increased risk to develop
substance dependence (104, 108). Moreover, in gambling disor-
der (GD) patients depressive symptoms predicted gambling urges
and duration (111). Allostasis framework enables us to extend
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Table 1 | Reward-system alterations and vulnerability to addiction in euthymic bipolar patients.
Aim Methods Sample Results Comments Reference
Trait-related
decision-
making
impairment
IGT, sensitivity-
to-punishment
index
167 BD (45
mania, 32
depressed, 90
euthymic), 150
HC
Manic, depressed, and euthymic BPs selected
significantly more cards from the risky decks than
HC. BD preferred decks that yielded infrequent
penalties over those yielding frequent penalties.
BD have a trait-related
impairment in
decision-making that does not
vary across illness phase,
predicted by high depressive
scores
(16)
Decision-
making
deficits;
temporal
discounting of
reward
Delay
discounting task
22 BD, 21 SZ,
30 HC
BD and SZ groups discounted delayed rewards
more steeply than did the healthy group (even after
controlling for current substance use). Working
memory or intelligence scores negatively
correlated with discounting rate.
BD patients value smaller,
immediate rewards more
than larger, delayed rewards
(18)
Neural
mechanisms
related to
motivation
fMRI,
probabilistic
reversal learning
task
19 BD, 19 HC,
22 relatives,
22 HC
Increased activation in response to reward and
reward reversal contingencies in the left medial
orbitofrontal cortex in BD. Activation of the
amygdala in response to reward reversal was
increased.
Increased activity of OFC and
amygdala, related to
heightened sensitivity to
reward and deficient
prediction error signal
(45)
Functional
brain
abnormalities
during reward
and working
memory
processing
fMRI, IGT,
n-back task
36 BD, 37 HC BD showed inefficient engagement within the
ventral frontopolar prefrontal cortex with
segregation along the medial–lateral dimension for
reward and working memory processing,
respectively. Greater activation in the anterior
cingulate cortex during the IGT and in the insula
during the n-back task.
Over-activation in regions
involved in emotional arousal
is present even in tasks that
do not typically engage
emotional systems
(69)
Hedonic
capacity
SHAPS,
SANS-An,
VAS-HC
107 BD, 86
MDD, 106 HC
SHAPS, SANS-An, and VAS scores significantly
higher in affective disorder patients. 20.5% of BDs
showed significant reduction in hedonic capacity
Reduced hedonic capacity
persists irrespective of mood
state
(84)
Relationship
between SUD
and
overweight-
obesity
Data from
CCHS, BMI
36,984
individuals
Overweight/obese bipolar individuals had a lower
rate of SUD than the normal weight sample (13 vs.
21%). BD+SUD had a lower rate of
overweight/obesity when compared with BD
non-SUD (39 vs. 54%)
Comorbid addictive disorders
may compete for the same
brain reward systems
(85)
Neural
correlates of
reward and
decision-
making
IGT, RDMUR,
ERP-assessed
RDGT
13 BD, 12
ADHD, 25 HC
BD group showed a pattern of enhanced ‘learning
by feedback’ and ‘sensitivity to reward magnitude’
regardless of valence. This ERP pattern was
associated with mood and inhibitory control.
Reduced responses of the cingulate cortex to the
valence and magnitude of rewards in BD.
Altered decision-making
process in BD with the
involvement of cingulate
cortex
(86)
Impulsivity BIS-11, stop
signal task,
delayed reward
task, continuous
performance
task
108 BD1
(1-year FU), 48
HC
At baseline (manic/mixed state), BD demonstrated
significant deficits on all three tasks. Performance
on the three behavioral tasks normalized upon
switching to depression or developing euthymia.
Elevated BIS-11 scores persist across phases of
illness.
Impulsivity has both
affective-state dependent and
trait components in BD.
(87)
Dysfunctional
reward
processing
Probabilistic
reward task
18 BD, 25 HC BD showed a reduced and delayed acquisition of
response bias toward the more frequently
rewarded stimulus
Dysfunctional reward learning
in situations requiring
integration of reinforcement
information in BD
(88)
(Continued)
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Table 1 | Continued
Aim Methods Sample Results Comments Reference
Risky decision-
making
(rewards vs
punishments)
Risky
decision-making
task
20 BD-2, DF,
20 HC
The BD participants overestimated the number of
bad outcomes arising out of positively framed
dilemmas. Risky choice in BD is associated with
reduced sensitivity to emotional contexts that
highlight rewards or punishments.
In BD, altered valuations of
prospective gains and losses
associated with behavioral
options.
(89)
Neural
correlates of
hypersensitiv-
ity to
immediate
reward
(1) Two choice
impulsivity
paradigm
(2) Delay
discounting
task, EEG
1) 32 subjects
2) 32 subjects
(1) The hypomania-prone group made significantly
more immediate choices than the control group.
(2) The hypomania-prone group evidenced greater
differentiation between delayed and immediate
outcomes in early attention-sensitive (N1) and later
reward-sensitive (feedback-related negativity)
components.
Provide support for reward
dysregulation accounts of BD,
characterizing neural
dynamics underlying
inter-temporal reward
processing
(90)
Substance
sensitivity and
sensation
seeking
SCID-I,
SCI-SUBS
57 BD1-SUD,
47 BD1, 35
SUD, 50 HC
BD+SUD and SUD have higher scores on
self-medication, substance sensitivity and
sensation seeking. No differences in reasons for
substance use between BD+SUD and SUD
(improving mood; relieving tension; alleviating
boredom; achieving/maintaining euphoria;
increasing energy).
In BD patients, substance
sensitivity and sensation
seeking traits are possible
factors associated with SUD
development
(91)
Reward
sensitivity and
positive affect
RPA; RRI;
BQL-BD
90 BD1, 72 HC The majority of BD-1 reported avoiding at least one
rewarding activity as a means of preventing mania.
Lower quality of life related to dampening positive
emotions.
People with BD-1 report
avoiding rewarding activities
and dampening positive
emotion
(92)
Neural
correlates of
hypersensitiv-
ity to
reward
fMRI,
anticipation and
outcome reward
task
21 BD1, 20 HC BD displayed greater ventral striatal and right-sided
OFC (BA 11) activity during anticipation, but not
outcome, of monetary reward. BD also displayed
elevated left-lateral OFC (BA 47) activity during
reward anticipation
Elevated ventral striatal and
OFC activity during reward
anticipation as a mechanism
underlying predisposition to
hypo/mania in response to
reward-relevant cues.
(93)
Sensitivity to
positive and
negative
feedback
Learning task
(posi-
tive/negative
feedback)
23 BD1, 19
MD, 19 HC
The quality of the last affective episode was the
only significant predictor. BD1 patients who last
experienced a manic episode learned well from
positive but not negative feedback, whereas BD1
patients who last experienced a depressive
episode showed the opposite pattern
Differences in response to
positive and negative
consequences carrying over
into the euthymic state are
related to the polarity of the
preceding episode
(94)
Motivational
aspects of
decision-
making in
relation to
reward and
punishment
IGT 28 BD (14
acute and 14
remitted) 25
HC
Acute BD were characterized by the tendency to
make erratic choices. Low choice consistency
improved the prediction of acute BD beyond that
provided by cognitive functioning and self-report
measures of personality and temperament.
Low choice consistency in BD
patients
(95)
BD, bipolar disorder; SZ, schizophrenia; HC, healthy controls; SUD, substance-use disorder; SCID-I, structured clinical interview for DSM-IV axis I disorders; SCI-SUBS,
structured clinical interview for the spectrum of substance use; DF, drug-free; SHAPS, Snaith–Hamilton pleasure scale; SANS-An, scale for the assessment of negative
symptoms, subscale for anhedonia/asociality; VAS-HC, visual analog scale for hedonic capacity; BIS-11, Barratt Impulsiveness Scale; RPA, responses to positive affect
measure; BQL-BD, brief quality of life in bipolar disorder scale; RRI, reward responses inventory; IGT, Iowa gambling task; RDMUR, task of rational decision-making
under risk; RDGT, rapid-decision gambling task; ERP, event-related potentials; fMRI, functional magnetic resonance imaging; EEG, electroencephalography; CCHS,
Canadian Community Health Survey-Mental Health andWell-Being; OFC, orbitofrontal cortex; BA, Brodmann area; FU, follow-up.
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FIGURE 1 | Allostatic alterations in bipolar disorder and vulnerability to
addiction. Throughout the involvement of enduring alterations in stress-
and reward-system, BD patients could experience a rapid transition from
occasional drug use to drug addiction. The occurrence of negative affective
states mediate the switch from impulsivity to compulsivity in bipolar
patients. Cumulative effects of mood episodes and substance use on
stress system have been hypothesized.
the self-medication theory (112) beyond the established clinical
domains, increasing the understanding of the interactions between
BD symptoms and substance use. For instance, euthymic bipo-
lar patients are more likely to experience cognitive impairment
(deficits in measures of executive functions, verbal learning, imme-
diate and delayed verbal memory, abstraction, sustained attention)
(113). Cannabis abuse seems to positively affect cognitive function
in a BD sample (114), and it may represent an attempt to counter-
balance these alterations, even though causing an increased risk of
rapid cycling and an earlier onset of manic episodes (114, 115).
Practitioners should be particularly vigilant in monitoring
for substance misuse early after the onset of mood disorders,
as well as they should be aware of personality traits related
to the risk of addiction, in particular antisocial and schizo-
typal personality disorder (11, 116). The existence of additional
risk factors [i.e., ADHD (117)] for the development of a BD-
SUD comorbidity is controversial (105, 118). Combined with
a specific role of traumatic stress as independent vulnerability-
factor (99, 119), these elements contribute to the build-up of
a cumulative AL. Clinicians can therefore incorporate specific
therapy approaches for dual disorders (120–122) to target adher-
ence weaknesses (123) and to enhance the effects of existing
treatments.
Given the notion that exposure to stress or drugs leads to endur-
ing changes in gene expression or activation of transcription fac-
tors, determining long-term neuroadaptation of brain functions,
a promising field of future research could involve the detection
of valuable markers of AL (124). In fact, markers of AL could
contribute to prevention strategy (105, 116, 125); moreover, they
could improve clinical monitoring and prognostic assessment of
comorbid patients.
The clinical management of BD-SUD subjects requires a careful
distinction between mood and withdrawal/intoxication symptoms
(126, 127). Neuroimaging studies indicate that brain regions
involved in mood regulation lie in close proximity to regions
involved in motivation and craving (128). The complex interplay
between addiction and BD domains, mediated by the involvement
of similar neurobiological systems, requires further studies to bet-
ter delineate how BD and SUD operate as reciprocal risk factors
(105, 129). Recently, it has been proposed to focus on some clinical
domain by using strategies aimed to treat both disorders simul-
taneously (101, 130). Besides reducing the recurrence of affective
episodes, and exerting neuroprotective, mood stabilizers have been
recently shown to have anti-anhedonic properties (131–134) with
potential utility in the treatment of comorbid conditions (135–
141). In addition, glutamatergic agents have been demonstrated
to be effective in the treatment of both mood (142) and addictive
disorders (82, 143); furthermore, they have been recently proposed
as a valuable therapeutic option in the treatment of comorbid
patients (139).
Future studies aimed at assessing brain AL in patients with
BD and addiction comorbidity may help to shed light on the
complex interactions underlying neurobiological vulnerability to
these disorders and to improve their treatment options. Early effec-
tive treatment strategies specifically devised for comorbid patients
(104, 125) could prevent, or possibly reverse, some of the neu-
robiological abnormalities and indicators of AL, thus potentially
leading to numerous benefits for these patients.
REFERENCES
1. Vornik LA, Brown ES. Management of comorbid bipolar disorder and sub-
stance abuse. J Clin Psychiatry (2006) 67(Suppl 7):24–30.
2. Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, et al. Preva-
lence, correlates, and comorbidity of bipolar I disorder and axis I and II
disorders: results from the National Epidemiologic Survey on alcohol and
related conditions. J Clin Psychiatry (2005) 66(10):1205–15. doi:10.4088/JCP.
v66n1001
3. Altamura AC. Bipolar spectrum and drug addiction. J Affect Disord (2007)
99(1–3):285. doi:10.1016/j.jad.2006.09.005
4. Di Nicola M, Tedeschi D, Mazza M, Martinotti G, Harnic D, Catalano V,
et al. Behavioural addictions in bipolar disorder patients: role of impul-
sivity and personality dimensions. J Affect Disord (2010) 125(1–3):82–8.
doi:10.1016/j.jad.2009.12.016
5. Pettorruso M, Di Nicola M, De Risio L, Fasano A, Martinotti G, Conte G, et al.
Punding behavior in bipolar disorder type 1: a case report. J Neuropsychiatry
Clin Neurosci (2014) 26(4):E8–9. doi:10.1176/appi.neuropsych.13090217
6. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comor-
bidity of mental disorders with alcohol and other drug abuse. Results from
the epidemiologic catchment area (ECA) study. JAMA (1990) 264(19):2511–8.
doi:10.1001/jama.1990.03450190043026
7. Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell’Osso MC, et al.
Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord
(2013) 148(2–3):161–9. doi:10.1016/j.jad.2013.02.001
8. Tsai HC, Lu MK, Yang YK, Huang MC, Yeh TL, Chen WJ, et al. Empirically
derived subgroups of bipolar I patients with different comorbidity patterns of
anxiety and substance use disorders in Han Chinese population. J Affect Disord
(2012) 136(1–2):81–9. doi:10.1016/j.jad.2011.08.015
9. Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: preva-
lence rate and treatment considerations. Bipolar Disord (2006) 8(6):677–85.
doi:10.1111/j.1399-5618.2006.00370.x
10. Mazza M,Mandelli L,Di Nicola M,Harnic D,CatalanoV,Tedeschi D,et al. Clin-
ical features, response to treatment and functional outcome of bipolar disorder
patients with and without co-occurring substance use disorder: 1-year follow-
up. J Affect Disord (2009) 115(1–2):27–35. doi:10.1016/j.jad.2008.08.019
11. Mandelli L, Mazza M, Di Nicola M, Zaninotto L, Harnic D, Catalano V, et al.
Role of substance abuse comorbidity and personality on the outcome of
Frontiers in Psychiatry | Addictive Disorders and Behavioral Dyscontrol December 2014 | Volume 5 | Article 173 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pettorruso et al. Allostasis, bipolar disorder, and addiction
depression in bipolar disorder: harm avoidance influences medium-term treat-
ment outcome. Psychopathology (2012) 45(3):174–8. doi:10.1159/000330364
12. McIntyre RS, Nguyen HT, Soczynska JK, Lourenco MT, Woldeyohannes HO,
Konarski JZ. Medical and substance-related comorbidity in bipolar disorder:
translational research and treatment opportunities. Dialogues Clin Neurosci
(2008) 10(2):203–13.
13. Carrà G, Bartoli F, Crocamo C, Brady KT, Clerici M. Attempted suicide in peo-
ple with co-occurring bipolar and substance use disorders: systematic review
and meta-analysis. J Affect Disord (2014) 167:125–35. doi:10.1016/j.jad.2014.
05.066
14. Yoon YH, Chen CM, Yi HY, Moss HB. Effect of comorbid alcohol and drug use
disorders on premature death among unipolar and bipolar disorder decedents
in the United States, 1999 to 2006. Compr Psychiatry (2011) 52(5):453–64.
doi:10.1016/j.comppsych.2010.10.005
15. Uhl GR, Drgon T, Johnson C, Li CY, Contoreggi C, Hess J, et al. Molec-
ular genetics of addiction and related heritable phenotypes: genome-wide
association approaches identify “connectivity constellation” and drug tar-
get genes with pleiotropic effects. Ann N Y Acad Sci (2008) 1141:318–81.
doi:10.1196/annals.1441.018
16. Adida M, Jollant F, Clark L, Besnier N, Guillaume S, Kaladjian A, et al. Trait-
related decision-making impairment in the three phases of bipolar disorder.
Biol Psychiatry (2011) 70(4):357–65. doi:10.1016/j.biopsych.2011.01.018
17. Adinoff B, Rilling LM, Williams MJ, Schreffler E, Schepis TS, Rosvall T, et al.
Impulsivity, neural deficits, and the addictions: the “oops” factor in relapse. J
Addict Dis (2007) 26(Suppl 1):25–39. doi:10.1300/J069v26S01_04
18. Ahn WY, Rass O, Fridberg DJ, Bishara AJ, Forsyth JK, Breier A, et al. Temporal
discounting of rewards in patients with bipolar disorder and schizophrenia. J
Abnorm Psychol (2011) 120(4):911–21. doi:10.1037/a0023333
19. Swann AC. The strong relationship between bipolar and substance-use dis-
order. Ann N Y Acad Sci (2010) 1187:276–93. doi:10.1111/j.1749-6632.2009.
05146.x
20. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology.
In: Fisher S, Reason J, editors. Handbook of Life Stress, Cognition and Health.
Chichester: John Wiley (1988). p. 629–49.
21. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann
N Y Acad Sci (1998) 840:33–44. doi:10.1111/j.1749-6632.1998.tb09546.x
22. McEwen BS. Allostasis and allostatic load: implications for neuropsy-
chopharmacology. Neuropsychopharmacology (2000) 22(2):108–24. doi:10.
1016/S0893-133X(99)00129-3
23. Brietzke E, Mansur RB, Soczynska J, Powell AM, McIntyre RS. A theoretical
framework informing research about the role of stress in the pathophysiol-
ogy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2012)
39(1):1–8. doi:10.1016/j.pnpbp.2012.05.004
24. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al.
Allostatic load in bipolar disorder: implications for pathophysiology and treat-
ment. Neurosci Biobehav Rev (2008) 32(4):675–92. doi:10.1016/j.neubiorev.
2007.10.005
25. Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis
and systemic toxicity in bipolar disorder. Physiol Behav (2012) 106(1):46–50.
doi:10.1016/j.physbeh.2011.10.029
26. Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, et al. The clinical
implications of cognitive impairment and allostatic load in bipolar disorder.
Eur Psychiatry (2013) 28(1):21–9. doi:10.1016/j.eurpsy.2011.11.007
27. Angelucci F, Ricci V, Gelfo F, Martinotti G, Brunetti M, Sepede G, et al. BDNF
serum levels in subjects developing or not post-traumatic stress disorder after
trauma exposure. Brain Cogn (2014) 84(1):118–22. doi:10.1016/j.bandc.2013.
11.012
28. Kapczinski F, Frey BN, Kauer-Sant’Anna M, Grassi-Oliveira R. Brain-derived
neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neu-
rother (2008) 8(7):1101–13. doi:10.1586/14737175.8.7.1101
29. Mandelli L, Mazza M, Martinotti G, Tavian D, Colombo E, Missaglia S,
et al. Further evidence supporting the influence of brain-derived neurotrophic
factor on the outcome of bipolar depression: independent effect of brain-
derived neurotrophic factor and harm avoidance. J Psychopharmacol (2010)
24(12):1747–54. doi:10.1177/0269881109353463
30. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M,
et al. Pathways underlying neuroprogression in bipolar disorder: focus on
inflammation, oxidative stress and neurotrophic factors.Neurosci Biobehav Rev
(2011) 35(3):804–17. doi:10.1016/j.neubiorev.2010.10.001
31. Grande I, Magalhães PV, Chendo I, Stertz L, Panizutti B, Colpo GD, et al. Stag-
ing systems in bipolar disorder: an International society for bipolar disorders
task force report.Acta Psychiatr Scand (2014) 130(5):354–63. doi:10.1111/acps.
12268
32. Schulkin J. Allostasis: a neural behavioral perspective. Horm Behav (2003)
43(1):21–7. doi:10.1016/S0018-506X(02)00035-1
33. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain
in depression and neurodegeneration. Ageing Res Rev (2005) 4(2):141–94.
doi:10.1016/j.arr.2005.03.003
34. Andreazza AC, Kauer-Sant’anna M, Frey BN, Bond DJ, Kapczinski F, Young
LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect
Disord (2008) 111(2–3):135–44. doi:10.1016/j.jad.2008.04.013
35. Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, et al. Increased
systemic cortisol metabolism in patients with schizophrenia and bipolar dis-
order: a mechanism for increased stress vulnerability? J Clin Psychiatry (2011)
72(11):1515–21. doi:10.4088/JCP.10m06068yel
36. Steen NE, Methlie P, Lorentzen S, Dieset I, Aas M, Nerhus M, et al.
Altered systemic cortisol metabolism in bipolar disorder and schizophrenia
spectrum disorders. J Psychiatr Res (2014) 52:57–62. doi:10.1016/j.jpsychires.
2014.01.017
37. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal
axis and bipolar disorder. Psychiatr Clin North Am (2005) 28(2):469–80.
doi:10.1016/j.psc.2005.01.005
38. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-
pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry
(2004) 184:496–502. doi:10.1192/bjp.184.6.496
39. McEwen BS. Structural plasticity of the adult brain: how animal models help
us understand brain changes in depression and systemic disorders related to
depression. Dialogues Clin Neurosci (2004) 6(2):119–33.
40. McEwen BS. Central effects of stress hormones in health and disease: under-
standing the protective and damaging effects of stress and stress mediators. Eur
J Pharmacol (2008) 583(2–3):174–85. doi:10.1016/j.ejphar.2007.11.071
41. Altman S, Haeri S, Cohen LJ, Ten A, Barron E, Galynker II, et al. Predictors
of relapse in bipolar disorder: a review. J Psychiatr Pract (2006) 12(5):269–82.
doi:10.1097/00131746-200609000-00002
42. Horesh N, Apter A, Zalsman G. Timing, quantity and quality of stressful life
events in childhood and preceding the first episode of bipolar disorder. J Affect
Disord (2011) 134(1–3):434–7. doi:10.1016/j.jad.2011.05.034
43. Lai MC, Huang LT. Effects of early life stress on neuroendocrine and neurobe-
havior: mechanisms and implications. Pediatr Neonatol (2011) 52(3):122–9.
doi:10.1016/j.pedneo.2011.03.008
44. Baker LM, Williams LM, Korgaonkar MS, Cohen RA, Heaps JM, Paul RH.
Impact of early vs. late childhood early life stress on brain morphometrics.
Brain Imaging Behav (2013) 7(2):196–203. doi:10.1007/s11682-012-9215-y
45. Linke J,King AV,Rietschel M,Strohmaier J,Hennerici M,Gass A,et al. Increased
medial orbitofrontal and amygdala activation: evidence for a systems-level
endophenotype of bipolar I disorder. Am J Psychiatry (2012) 169(3):316–25.
doi:10.1176/appi.ajp.2011.11050711
46. Koob GF, Buck CL, Cohen A, Edwards S, Park PE, Schlosburg JE, et al. Addic-
tion as a stress surfeit disorder. Neuropharmacology (2014) 76(Pt B):370–82.
doi:10.1016/j.neuropharm.2013.05.024
47. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis.
Neuropsychopharmacology (2001) 24(2):97–129. doi:10.1016/S0893-133X(00)
00195-0
48. Koob GF. Addiction is a reward deficit and stress surfeit disorder. Front Psychi-
atry (2013) 4:72. doi:10.3389/fpsyt.2013.00072
49. George O, Le Moal M, Koob GF. Allostasis and addiction: role of the dopamine
and corticotropin-releasing factor systems. Physiol Behav (2012) 106(1):58–64.
doi:10.1016/j.physbeh.2011.11.004
50. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and
the transition to drug dependence. Am J Psychiatry (2007) 164(8):1149–59.
doi:10.1176/appi.ajp.2007.05030503
51. Pettorruso M, Martinotti G, Fasano A, Loria G, Di Nicola M, De Risio L,
et al. Anhedonia in Parkinson’s disease patients with and without patho-
logical gambling: a case-control study. Psychiatry Res (2014) 215(2):448–52.
doi:10.1016/j.psychres.2013.12.013
52. Koob GF. Neurobiological substrates for the dark side of compulsivity
in addiction. Neuropharmacology (2009) 56(Suppl 1):18–31. doi:10.1016/j.
neuropharm.2008.07.043
www.frontiersin.org December 2014 | Volume 5 | Article 173 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pettorruso et al. Allostasis, bipolar disorder, and addiction
53. Gilpin NW. Brain reward and stress systems in addiction. Front Psychiatry
(2014) 5:79. doi:10.3389/fpsyt.2014.00079
54. Koob GF. A role for brain stress systems in addiction. Neuron (2008)
59(1):11–34. doi:10.1016/j.neuron.2008.06.012
55. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev
Psychol (2008) 59:29–53. doi:10.1146/annurev.psych.59.103006.093548
56. Koob GF. Hedonic homeostatic dysregulation as a driver of drug-seeking
behavior. Drug Discov Today Dis Models (2008) 5(4):207–15. doi:10.1016/j.
ddmod.2009.04.002
57. Koob GF. Neuroadaptive mechanisms of addiction: studies on the extended
amygdala. Eur Neuropsychopharmacol (2003) 13(6):442–52. doi:10.1016/j.
euroneuro.2003.08.005
58. Koob GF. The role of CRF and CRF-related peptides in the dark side of addic-
tion. Brain Res (2010) 1314:3–14. doi:10.1016/j.brainres.2009.11.008
59. Martinotti G, Nicola MD, Reina D, Andreoli S, Focà F, Cunniff A, et al. Alco-
hol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse
(2008) 43(3–4):271–84. doi:10.1080/10826080701202429
60. Valdez GR, Koob GF. Allostasis and dysregulation of and neuropeptide Y sys-
tems: implications for the development of alcoholism. Pharmacol Biochem
Behav (2004) 79(4):671–89. doi:10.1016/j.pbb.2004.09.020
61. Carmiol N, Peralta JM, Almasy L, Contreras J, Pacheco A, Escamilla MA,
et al. Shared genetic factors influence risk for bipolar disorder and alcohol
use disorders. Eur Psychiatry (2014) 29(5):282–7. doi:10.1016/j.eurpsy.2013.
10.001
62. Mandelli L, Mazza M, Marangoni C, Di Nicola M, Martinotti G, Tavian D, et al.
Preliminary analysis of genes involved in inflammatory, oxidative processes and
CA2+signaling in bipolar disorder and comorbidity for substance use disorder.
Clin Neuropsychiatry (2011) 8(6):347–53.
63. Johnson C, Drgon T, McMahon FJ, Uhl GR. Convergent genome wide associ-
ation results for bipolar disorder and substance dependence. Am J Med Genet
B Neuropsychiatr Genet (2009) 150B(2):182–90. doi:10.1002/ajmg.b.30900
64. Levey DF, Le-Niculescu H, Frank J,Ayalew M, Jain N, Kirlin B, et al. Genetic risk
prediction and neurobiological understanding of alcoholism. Transl Psychiatry
(2014) 4:e391. doi:10.1038/tp.2014.29
65. Patel SD, Le-Niculescu H, Koller DL, Green SD, Lahiri DK, McMahon FJ,
et al. Coming to grips with complex disorders: genetic risk prediction in bipo-
lar disorder using panels of genes identified through convergent functional
genomics. Am J Med Genet B Neuropsychiatr Genet (2010) 153B(4):850–77.
doi:10.1002/ajmg.b.31087
66. Haldane M, Frangou S. New insights help define the pathophysiology of bipolar
affective disorder: neuroimaging and neuropathology findings. Prog Neuropsy-
chopharmacol Biol Psychiatry (2004) 28(6):943–60. doi:10.1016/j.pnpbp.2004.
05.040
67. Wallis JD, Miller EK. Neuronal activity in primate dorsolateral and orbital pre-
frontal cortex during performance of a reward preference task. Eur J Neurosci
(2003) 18(7):2069–81. doi:10.1046/j.1460-9568.2003.02922.x
68. Frangou S, Kington J, Raymont V, Shergill SS. Examining ventral and
dorsal prefrontal function in bipolar disorder: a functional magnetic resonance
imaging study. Eur Psychiatry (2008) 23(4):300–8. doi:10.1016/j.eurpsy.2007.
05.002
69. Jogia J, Dima D, Kumari V, Frangou S. Frontopolar cortical inefficiency may
underpin reward and working memory dysfunction in bipolar disorder. World
J Biol Psychiatry (2012) 13(8):605–15. doi:10.3109/15622975.2011.585662
70. Young JW, van Enkhuizen J, Winstanley CA, Geyer MA. Increased risk-
taking behavior in dopamine transporter knockdown mice: further sup-
port for a mouse model of mania. J Psychopharmacol (2011) 25(7):934–43.
doi:10.1177/0269881111400646
71. Camardese G, Di Giuda D, Di Nicola M, Cocciolillo F, Giordano A, Janiri L,
et al. Imaging studies on dopamine transporter and depression: a review of
literature and suggestions for future research. J Psychiatr Res (2014) 51:7–18.
doi:10.1016/j.jpsychires.2013.12.006
72. Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C, et al.
A study of the dopamine D2 receptor gene in pathological gambling. Pharma-
cogenetics (1996) 6(3):223–34. doi:10.1097/00008571-199606000-00004
73. van Enkhuizen J, Geyer MA, Young JW. Differential effects of dopamine
transporter inhibitors in the rodent Iowa gambling task: relevance to mania.
Psychopharmacology (Berl) (2013) 225(3):661–74. doi:10.1007/s00213-012-
2854-2
74. van Enkhuizen J, Henry BL, Minassian A, Perry W, Milienne-Petiot M, Higa KK,
et al. Reduced dopamine transporter functioning induces high-reward risk-
preference consistent with bipolar disorder. Neuropsychopharmacology (2014)
39(13):3112–22. doi:10.1038/npp.2014.170
75. Berk M, Dodd S, Kauer-Sant’anna M, Malhi GS, Bourin M, Kapczinski
F, et al. Dopamine dysregulation syndrome: implications for a dopamine
hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl (2007) 434:41–9.
doi:10.1111/j.1600-0447.2007.01058.x
76. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar
disorder. Bipolar Disord (2009) 11(8):787–806. doi:10.1111/j.1399-5618.2009.
00760.x
77. Diana M. The dopamine hypothesis of drug addiction and its potential thera-
peutic value. Front Psychiatry (2011) 2:64. doi:10.3389/fpsyt.2011.00064
78. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-
related deficits. Trends Neurosci (2012) 35(1):68–77. doi:10.1016/j.tins.2011.
11.005
79. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, Janiri L. Anhedonia and
substance dependence: clinical correlates and treatment options. Front Psychi-
atry (2011) 2:10. doi:10.3389/fpsyt.2011.00010
80. Kirby LG, Zeeb FD, Winstanley CA. Contributions of serotonin in addic-
tion vulnerability. Neuropharmacology (2011) 61(3):421–32. doi:10.1016/j.
neuropharm.2011.03.022
81. Van den Oever MC, Spijker S, Smit AB. The synaptic pathology of drug
addiction. Adv Exp Med Biol (2012) 970:469–91. doi:10.1007/978-3-7091-
0932-8_21
82. Pettorruso M, De Risio L, Martinotti G, Di Nicola M, Ruggeri F, Conte G,
et al. Targeting the glutamatergic system to treat pathological gambling: cur-
rent evidence and future perspectives. Biomed Res Int (2014) 2014:109786.
doi:10.1155/2014/109786
83. Pettorruso M, Martinotti G, Di Nicola M, Onofrj M, Di Giannantonio M, Conte
G, et al. Amantadine in the treatment of pathological gambling: a case report.
Front Psychiatry (2012) 3:102. doi:10.3389/fpsyt.2012.00102
84. Di Nicola M, De Risio L, Battaglia C, Camardese G, Tedeschi D, Mazza M, et al.
Reduced hedonic capacity in euthymic bipolar subjects: a trait-like feature? J
Affect Disord (2013) 147(1–3):446–50. doi:10.1016/j.jad.2012.10.004
85. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Bottas A, Castel S, et al.
Substance use disorders and overweight/obesity in bipolar I disorder: prelimi-
nary evidence for competing addictions. J Clin Psychiatry (2007) 68(9):1352–7.
doi:10.4088/JCP.v68n0905
86. Ibanez A, Cetkovich M, Petroni A, Urquina H, Baez S, Gonzalez-Gadea ML,
et al. The neural basis of decision-making and reward processing in adults with
euthymic bipolar disorder or attention-deficit/hyperactivity disorder (ADHD).
PLoS One (2012) 7(5):e37306. doi:10.1371/journal.pone.0037306
87. Strakowski SM, Fleck DE, DelBello MP, Adler CM, Shear PK, Kotwal R,
et al. Impulsivity across the course of bipolar disorder. Bipolar Disord (2010)
12(3):285–97. doi:10.1111/j.1399-5618.2010.00806.x
88. Pizzagalli DA, Goetz E, Ostacher M, Iosifescu DV, Perlis RH. Euthymic patients
with bipolar disorder show decreased reward learning in a probabilistic
reward task. Biol Psychiatry (2008) 64(2):162–8. doi:10.1016/j.biopsych.2007.
12.001
89. Chandler RA, Wakeley J, Goodwin GM, Rogers RD. Altered risk-aversion and
risk-seeking behavior in bipolar disorder. Biol Psychiatry (2009) 66(9):840–6.
doi:10.1016/j.biopsych.2009.05.011
90. Mason L, O’Sullivan N, Blackburn M, Bentall R, El-Deredy W. I want it now!
neural correlates of hypersensitivity to immediate reward in hypomania. Biol
Psychiatry (2012) 71(6):530–7. doi:10.1016/j.biopsych.2011.10.008
91. Bizzarri JV, Sbrana A, Rucci P, Ravani L, Massei GJ, Gonnelli C, et al. The
spectrum of substance abuse in bipolar disorder: reasons for use, sensa-
tion seeking and substance sensitivity. Bipolar Disord (2007) 9(3):213–20.
doi:10.1111/j.1399-5618.2007.00383.x
92. Edge MD, Miller CJ, Muhtadie L, Johnson SL, Carver CS, Marquinez N,
et al. People with bipolar I disorder report avoiding rewarding activities
and dampening positive emotion. J Affect Disord (2013) 146(3):407–13.
doi:10.1016/j.jad.2012.07.027
93. Nusslock R, Almeida JR, Forbes EE, Versace A, Frank E, Labarbara EJ, et al.
Waiting to win: elevated striatal and orbitofrontal cortical activity during
reward anticipation in euthymic bipolar disorder adults. Bipolar Disord (2012)
14(3):249–60. doi:10.1111/j.1399-5618.2012.01012.x
Frontiers in Psychiatry | Addictive Disorders and Behavioral Dyscontrol December 2014 | Volume 5 | Article 173 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pettorruso et al. Allostasis, bipolar disorder, and addiction
94. Linke J, Sonnekes C, Wessa M. Sensitivity to positive and negative feedback in
euthymic patients with bipolar I disorder: the last episode makes the difference.
Bipolar Disord (2011) 13(7–8):638–50. doi:10.1111/j.1399-5618.2011.00956.x
95. Yechiam E, Hayden EP, Bodkins M, O’Donnell BF, Hetrick WP. Decision mak-
ing in bipolar disorder: a cognitive modeling approach. Psychiatry Res (2008)
161(2):142–52. doi:10.1016/j.psychres.2007.07.001
96. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and inte-
grated model.AnnuRevClin Psychol (2014) 10:393–423. doi:10.1146/annurev-
clinpsy-050212-185606
97. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann NYAcad
Sci (2008) 1141:105–30. doi:10.1196/annals.1441.030
98. Lovallo WR. Cortisol secretion patterns in addiction and addiction risk. Int J
Psychophysiol (2006) 59(3):195–202. doi:10.1016/j.ijpsycho.2005.10.007
99. Lijffijt M, Hu K, Swann AC. Stress modulates illness-course of substance use
disorders: a translational review. Front Psychiatry (2014) 5:83. doi:10.3389/
fpsyt.2014.00083
100. Levy YZ, Levy DJ, Barto AG, Meyer JS. A computational hypothesis for allosta-
sis: delineation of substance dependence, conventional therapies, and alterna-
tive treatments. Front Psychiatry (2013) 4:167. doi:10.3389/fpsyt.2013.00167
101. Post RM, Kalivas P. Bipolar disorder and substance misuse: pathological and
therapeutic implications of their comorbidity and cross-sensitisation. Br J Psy-
chiatry (2013) 202(3):172–6. doi:10.1192/bjp.bp.112.116855
102. Azorin JM, Bellivier F, Kaladjian A, Adida M, Belzeaux R, Fakra E, et al. Char-
acteristics and profiles of bipolar I patients according to age-at-onset: find-
ings from an admixture analysis. J Affect Disord (2013) 150(3):993–1000.
doi:10.1016/j.jad.2013.05.026
103. Pope MA, Joober R, Malla AK. Diagnostic stability of first-episode psychotic
disorders and persistence of comorbid psychiatric disorders over 1 year. Can J
Psychiatry (2013) 58(10):588–94.
104. Goldstein BI, Strober M,Axelson D, Goldstein TR, Gill MK, Hower H, et al. Pre-
dictors of first-onset substance use disorders during the prospective course of
bipolar spectrum disorders in adolescents. J Am Acad Child Adolesc Psychiatry
(2013) 52(10):1026–37. doi:10.1016/j.jaac.2013.07.009
105. Kenneson A, Funderburk JS, Maisto SA. Risk factors for secondary substance
use disorders in people with childhood and adolescent-onset bipolar dis-
order: opportunities for prevention. Compr Psychiatry (2013) 54(5):439–46.
doi:10.1016/j.comppsych.2012.12.008
106. Duffy A, Horrocks J, Milin R, Doucette S, Persson G, Grof P. Adolescent sub-
stance use disorder during the early stages of bipolar disorder: a prospective
high-risk study. J Affect Disord (2012) 142(1–3):57–64. doi:10.1016/j.jad.2012.
04.010
107. Do EK, Mezuk B. Comorbidity between hypomania and substance use disor-
ders. J Affect Disord (2013) 150(3):974–80. doi:10.1016/j.jad.2013.05.023
108. Prisciandaro JJ, DeSantis SM, Chiuzan C, Brown DG, Brady KT, Tolliver BK.
Impact of depressive symptoms on future alcohol use in patients with co-
occurring bipolar disorder and alcohol dependence: a prospective analysis in
an 8-week randomized controlled trial of acamprosate. Alcohol Clin Exp Res
(2012) 36(3):490–6. doi:10.1111/j.1530-0277.2011.01645.x
109. Saddichha S, Prakash R, Sinha BN, Khess CR. Perceived reasons for and con-
sequences of substance abuse among patients with psychosis. Prim Care Com-
panion J Clin Psychiatry (2010) 12(5):e1–7. doi:10.4088/PCC.09m00926gry
110. Pettersen H, Ruud T, Ravndal E, Landheim A. Walking the fine line: self-
reported reasons for substance use in persons with severe mental illness. Int J
Qual Stud Health Well-being (2013) 8:21968. doi:10.3402/qhw.v8i0.21968
111. Rømer Thomsen K, Callesen MB, Linnet J, Kringelbach ML, Møller A. Sever-
ity of gambling is associated with severity of depressive symptoms in patho-
logical gamblers. Behav Pharmacol (2009) 20(5–6):527–36. doi:10.1097/FBP.
0b013e3283305e7a
112. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on
heroin and cocaine dependence. Am J Psychiatry (1985) 142(11):1259–64.
113. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN,
et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar
disorder. J Affect Disord (2006) 93(1–3):105–15. doi:10.1016/j.jad.2006.02.016
114. Bally N, Zullino D, Aubry JM. Cannabis use and first manic episode. J Affect
Disord (2014) 165:103–8. doi:10.1016/j.jad.2014.04.038
115. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-
occurring cannabis use disorders: characteristics, co-morbidities and clinical
correlates. Psychiatry Res (2013) 209(3):459–65. doi:10.1016/j.psychres.2012.
12.014
116. Baigent M. Managing patients with dual diagnosis in psychiatric practice. Curr
Opin Psychiatry (2012) 25(3):201–5. doi:10.1097/YCO.0b013e3283523d3d
117. Di Nicola M, Sala L, Romo L, Catalano V, Even C, Dubertret C, et al. Adult
attention-deficit/hyperactivity disorder in major depressed and bipolar sub-
jects: role of personality traits and clinical implications. Eur Arch Psychiatry
Clin Neurosci (2014) 264(5):391–400. doi:10.1007/s00406-013-0456-6
118. Perugi G, Ceraudo G, Vannucchi G, Rizzato S, Toni C, Dell’Osso L. Attention
deficit/hyperactivity disorder symptoms in Italian bipolar adult patients: a pre-
liminary report. J Affect Disord (2013) 149(1–3):430–4. doi:10.1016/j.jad.2012.
12.010
119. Sala R, Goldstein BI,Wang S, Blanco C. Childhood maltreatment and the course
of bipolar disorders among adults: epidemiologic evidence of dose-response
effects. J Affect Disord (2014) 165:74–80. doi:10.1016/j.jad.2014.04.035
120. Jones SH, Barrowclough C, Allott R, Day C, Earnshaw P, Wilson I. Integrated
motivational interviewing and cognitive-behavioural therapy for bipolar disor-
der with comorbid substance use.Clin Psychol Psychother (2011) 18(5):426–37.
doi:10.1002/cpp.783
121. Gaudiano BA, Weinstock LM, Miller IW. Improving treatment adherence in
patients with bipolar disorder and substance abuse: rationale and initial devel-
opment of a novel psychosocial approach. J Psychiatr Pract (2011) 17(1):5–20.
doi:10.1097/01.pra.0000393840.18099.d6
122. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for peo-
ple with co-occurring severe mental illnesses and substance use disorders
(dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry (2009)
17(1):24–34. doi:10.1080/10673220902724599
123. Murru A, Pacchiarotti I, Amann BL, Nivoli AM, Vieta E, Colom F. Treatment
adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord
(2013) 151(3):1003–8. doi:10.1016/j.jad.2013.08.026
124. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress
and impact on health and cognition. Neurosci Biobehav Rev (2010) 35(1):2–16.
doi:10.1016/j.neubiorev.2009.10.002
125. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth
with bipolar disorder: opportunities for early identification and prevention. J
Clin Psychiatry (2010) 71(3):348–58. doi:10.4088/JCP.09r05222gry
126. Langas AM, Malt UF, Opjordsmoen S. Independent versus substance-induced
major depressive disorders in first-admission patients with substance use disor-
ders: an exploratory study. J Affect Disord (2013) 144(3):279–83. doi:10.1016/
j.jad.2012.10.008
127. Quello SB, Brady KT, Sonne SC. Mood disorders and substance use disor-
der: a complex comorbidity. Sci Pract Perspect (2005) 3(1):13–21. doi:10.1151/
spp053113
128. Li CS, Sinha R. Inhibitory control and emotional stress regulation: neuroimag-
ing evidence for frontal-limbic dysfunction in psycho-stimulant addiction.
Neurosci Biobehav Rev (2008) 32(3):581–97. doi:10.1016/j.neubiorev.2007.10.
003
129. Kenneson A, Funderburk JS, Maisto SA. Substance use disorders increase
the odds of subsequent mood disorders. Drug Alcohol Depend (2013)
133(2):338–43. doi:10.1016/j.drugalcdep.2013.06.011
130. Pettinati HM, O’Brien CP, Dundon WD. Current status of co-occurring mood
and substance use disorders: a new therapeutic target. Am J Psychiatry (2013)
170(1):23–30. doi:10.1176/appi.ajp.2012.12010112
131. Marchese G, Scheggi S, Secci ME, De Montis MG, Gambarana C. Anti-
anhedonic activity of long-term lithium treatment in rats exposed to repeated
unavoidable stress. Int J Neuropsychopharmacol (2013) 16(7):1611–21. doi:10.
1017/S1461145712001654
132. Orsetti M, Canonico PL, Dellarole A, Colella L, Di Brisco F, Ghi P. Quetiapine
prevents anhedonia induced by acute or chronic stress. Neuropsychopharma-
cology (2007) 32(8):1783–90. doi:10.1038/sj.npp.1301291
133. Marston HM, Martin FD, Papp M, Gold L, Wong EH, Shahid M. Attenuation
of chronic mild stress-induced ‘anhedonia’ by asenapine is not associated with
a ‘hedonic’ profile in intracranial self-stimulation. J Psychopharmacol (2011)
25(10):1388–98. doi:10.1177/0269881110376684
134. Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P. Effect of aripiprazole on
self-reported anhedonia in bipolar depressed patients. Psychiatry Res (2009)
165(1–2):193–6. doi:10.1016/j.psychres.2008.05.003
www.frontiersin.org December 2014 | Volume 5 | Article 173 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pettorruso et al. Allostasis, bipolar disorder, and addiction
135. Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone
M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychi-
atric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol (2008)
23(5):417–24. doi:10.1002/hup.944
136. Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disor-
ders and baseline medication regimens predict clinical outcomes in individuals
with co-occurring bipolar disorder and alcohol dependence: results of a ran-
domized controlled trial. Psychiatry Res (2011) 188(3):361–5. doi:10.1016/j.
psychres.2011.04.030
137. Di Nicola M, Martinotti G, Mazza M, Tedeschi D, Pozzi G, Janiri L. Quetiapine
as add-on treatment for bipolar I disorder with comorbid compulsive buying
and physical exercise addiction. Prog Neuropsychopharmacol Biol Psychiatry
(2010) 34(4):713–4. doi:10.1016/j.pnpbp.2010.03.013
138. Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and
craving in alcohol-dependent subjects: results from a pilot study. J Clin Psy-
chopharmacol (2007) 27(5):519–20. doi:10.1097/JCP.0b013e318150c841
139. Di Nicola M, De Risio L, Pettorruso M, Caselli G, De Crescenzo F, Swierkosz-
Lenart K, et al. Bipolar disorder and gambling disorder comorbidity: cur-
rent evidence and implications for pharmacological treatment. J Affect Disord
(2014) 167:285–98. doi:10.1016/j.jad.2014.06.023
140. Beaulieu S, Saury S, Sareen J, Tremblay J, Schütz CG, McIntyre RS, et al. The
canadian network for mood and anxiety treatments (CANMAT) task force
recommendations for the management of patients with mood disorders and
comorbid substance use disorders. Ann Clin Psychiatry (2012) 24(1):38–55.
141. Sani G, Kotzalidis GD, Vöhringer P, Pucci D, Simonetti A, Manfredi G, et al.
Effectiveness of short-term olanzapine in patients with bipolar I disorder, with
or without comorbidity with substance use disorder. J Clin Psychopharmacol
(2013) 33(2):231–5. doi:10.1097/JCP.0b013e318287019c
142. Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr. Novel glutamatergic
agents for major depressive disorder and bipolar disorder. Pharmacol Biochem
Behav (2012) 100(4):678–87. doi:10.1016/j.pbb.2011.09.010
143. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for
the treatment of drug and behavioral addictions. Pharmacol Biochem Behav
(2012) 100(4):801–10. doi:10.1016/j.pbb.2011.04.015
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 31 March 2014; accepted: 16 November 2014; published online: 03 December
2014.
Citation: Pettorruso M, De Risio L, Di Nicola M, Martinotti G, Conte G and Janiri
L (2014) Allostasis as a conceptual framework linking bipolar disorder and addiction.
Front. Psychiatry 5:173. doi: 10.3389/fpsyt.2014.00173
This article was submitted to Addictive Disorders and Behavioral Dyscontrol, a section
of the journal Frontiers in Psychiatry.
Copyright © 2014 Pettorruso, De Risio, Di Nicola,Martinotti, Conte and Janiri. This is
an open-access article distributed under the terms of the Creative CommonsAttribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Psychiatry | Addictive Disorders and Behavioral Dyscontrol December 2014 | Volume 5 | Article 173 | 10
